This trial is evaluating whether EHR CDS will improve 1 primary outcome and 5 secondary outcomes in patients with Alzheimer Disease. Measurement will happen over the course of 90 days.
This trial requires 117 total participants across 2 different treatment groups
This trial involves 2 different treatments. EHR CDS is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"There is a variety of treatment for patients with AD; however, many patients use alternative treatments over traditional medical remedies. The more common medications used in patients included acetylcholinesterase inhibitors (AChEIs), such as donepezil, galantamine, or rivastigmine; non-AChEIs, such as memantine; and other medications, such as selective serotonin reuptake inhibitors (SSRIs) and other antidepressants. The incidence of these medications is higher than that of conventional care. There is limited support for alternative medicine therapies; however, further research is needed." - Anonymous Online Contributor
"Results from a recent clinical trial of our study suggest that the presence of NOS-D as a co-morbidity in AD patients may represent a marker of a worse long-acting form of dementia that warrants further treatment of NOS-Ds." - Anonymous Online Contributor
"Alzheimer disease is a neurological disorder characterised by declining memory, thinking difficulties and a progressive decrease in the ability to live independently and to function independently of others. There was a shortage of healthcare professionals in China who could diagnose and treat the disease. The condition was not widely recognized, and there was a low awareness of Alzheimer's disease." - Anonymous Online Contributor
"At present, there is not a single cause that explains all cases of the disease. The causes are most likely manifold and complex, having to do with genetic, neurological, and environmental factors. The major risk factor is, however, aging.\n" - Anonymous Online Contributor
"1. About 24 percent of Medicare beneficiaries are diagnosed with Alzheimer disease in some 12-year interval, and a comparable proportion have Alzheimer-related diagnoses made in clinical research databases." - Anonymous Online Contributor
"In order to help the patient to be familiar with the symptoms of dementia, the health care facilities should ask the patient about their memory, socializing activities, use of medications, and how much they sleep. It is possible to identify the patient's social-cultural risk factors and implement appropriate interventions." - Anonymous Online Contributor
"There is a high prevalence of abnormal or non-uniform EEGs as detected in one of every three patients evaluated for epilepsy in a tertiary care hospital in Miami, Florida, as well as in a community setting. Normal EEGs are uncommon. This adds further support to the notion that many patients who complain of epilepsy do not have it, as documented in studies conducted in South Carolina and in a community setting in Florida. Results from a recent paper suggest the need for additional evaluation and treatment to be performed outside of the usual confines of tertiary care epilepsy centers." - Anonymous Online Contributor
"AD Clinical Trial Publications is currently the most authoritative source of current information for all AD Clinical Trials. As the majority of studies on AD clinical trials that received peer reviewer approval report conclusions only in the abstract, we feel that the Abstracts section of this article offers the latest knowledge accessible for the general public." - Anonymous Online Contributor
"While there is a lot of promising research on alzheimer disease treatment, there is no current cure for it. However, there are drug companies working to find one. The only way to find out is with the help of research scientists." - Anonymous Online Contributor
"answer: Clinical trials are generally accepted by the public and health care providers with few known side effects. This may make them an excellent option for treatment; however, they may not be the perfect solution to treat a wide variety of conditions. Therefore, careful consideration of both research methodology and side effects is advised when considering clinical trials." - Anonymous Online Contributor
"The study design of the Ehr Study could not detect or assess the effectiveness of Ehr in combination with any form of treatment in patients with AlzHD. Data from a recent study found that the use of a combination of Ehr CDS and any other treatment was not appropriate or beneficial." - Anonymous Online Contributor
"This is a preliminary report on a treatment program for Alzheimer disease with [Cognitive, Functional, Behavioral and Communicative Decline (CFBDC)] components. This treatment program has been completed with [no patient lost to follow-up] and [no adverse event reported]." - Anonymous Online Contributor